Physician profile
Ryan Alan Brown
NPI 1467425439
$8,361.37
in general payments reported to CMS, 2019-2025
41 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $299 · 2021: $825 · 2022: $1,506 · 2023: $1,976 · 2024: $1,615 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,366.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $1,010.37 | 2019-2022 | |
| Boston Scientific Corporation | $726.65 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Bodyguardian |
| Edwards Lifesciences Corporation | $679.54 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $611.54 | 2019-2025 | Lifevest |
| Cvrx, INC. | $544.05 | 2022-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.98 | 2019-2025 | Jardiance |
| Abbott Laboratories | $377.29 | 2020-2025 | Cardiomems, Amplatzer Amulet, Dragonfly Opstar |
| Medtronic, INC. | $356.06 | 2021-2023 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $309.49 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $307.55 | 2023-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $306.33 | 2020-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $248.46 | 2023-2025 | Verquvo, Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $237.50 | 2023-2025 | |
| Abiomed | $224.27 | 2021-2025 | Impella |
| Amgen INC. | $216.62 | 2019-2025 | Repatha, Repatha |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $195.09 | 2023-2025 | Nexletol |
| Novo Nordisk INC | $191.52 | 2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $191.31 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $157.57 | 2024-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $132.73 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $128.98 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $93.80 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $91.85 | 2024 | Arcalyst |
| Heartflow, INC. | $85.87 | 2023-2025 | Ffrct |
| Biotronik INC. | $50.30 | 2023 | Edora 8 Dr-T |
| Inspire Medical Systems, INC. | $43.58 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $42.60 | 2023 | Opsumit, Uptravi |
| Inari Medical, INC. | $37.56 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $35.00 | 2023 | |
| Philips North America LLC | $31.50 | 2025 | Igt Devices Systems Undivided |
| Cathworks, INC. | $31.06 | 2023 | Ffrangio |
| Pfizer INC. | $30.78 | 2019-2025 | |
| Penumbra, INC. | $28.39 | 2024 | Indigo System |
| Daiichi Sankyo INC. | $24.27 | 2023 | Injectafer |
| Medtronic Vascular, INC. | $24.00 | 2019 | |
| Biogen, INC. | $23.69 | 2024 | Skyclarys |
| Lilly USA, LLC | $21.25 | 2025 | Zepbound, Mounjaro |
| Ultragenyx Pharmaceutical INC. | $21.14 | 2025 | Dojolvi |
| Regeneron Healthcare Solutions, INC. | $20.59 | 2024 | Evkeeza |
| Scpharmaceuticals INC. | $17.85 | 2025 | |
| Kestra Medical Technology Services, INC. | $14.39 | 2024 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.